永赢医药创新智选混合发起C(015916)财务指标
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 本期已实现收益 |
27,909,356.23 |
166,925,109.80 |
85,352,028.18 |
-43,310,481.76 |
| 本期利润 |
-242,487,011.14 |
-6,062,835.07 |
400,643,218.05 |
-34,993,830.19 |
| 加权平均基金份额本期利润 |
-0.08 |
0.00 |
0.50 |
-0.16 |
| 本期加权平均净值利润率(%) |
-4.84 |
-0.18 |
37.83 |
-17.56 |
| 本期基金份额净值增长率(%) |
-2.94 |
73.89 |
68.97 |
-12.44 |
| 期末可供分配利润 |
-539,645,116.68 |
-583,913,668.97 |
-417,995,745.97 |
-51,990,687.61 |
| 期末可供分配基金份额利润 |
-0.18 |
-0.19 |
-0.24 |
-0.32 |
| 期末基金资产净值 |
4,468,216,451.14 |
4,760,937,732.40 |
2,704,548,024.57 |
146,465,541.98 |
| 期末基金份额净值 |
1.52 |
1.57 |
1.52 |
0.90 |
| 基金份额累计净值增长率(%) |
51.94 |
56.54 |
52.11 |
-9.98 |
微信公众号
证券之星APP
基本资料
